ascopubs.org

Updated results from a phase I/II study of CBP-1018, a bi-ligand–drug conjugate (Bi-XDC) as late line therapy for patients with metastatic castration resistant prostate ...

PERSIAN trial: Early results from a randomized phase II trial testing apalutamide and stereotactic body radiation therapy for low-burden, metastatic, hormone-sensitive prostate cancer. This is an ASCO ...
ascopubs.org

A phase 1, multi-center, open-label, dose-escalation, and dose-expansion study of CBP-1018, a bi-ligand-drug conjugate in patients with heavily treated advanced solid tumors.

Effect of concomitant medications on treatment response and survival in non-metastatic castrate resistant prostate cancer: Secondary analysis of the SPARTAN trial. This is an ASCO Meeting Abstract ...